Navigation Links
Karyopharm Therapeutics Inc. and Katholieke Universiteit Leuven Sign Exclusive Collaboration for the Discovery of Novel CRM1/Exportin 1 Inhibitors
Date:10/11/2011

NATICK, Mass., Oct. 11, 2011 /PRNewswire/ -- Karyopharm Therapeutics Inc., a leader in the new field of nuclear transport modulators, has initiated an exclusive collaboration in the area of Selective Inhibitors of Nuclear Export (SINE) modulators of the CRM1 protein with the Rega Institute for Medical Research, a part of the Katholieke University of Leuven (K.U.Leuven), Belgium. The nuclear transport machinery plays an integral role in the regulation of many molecules involved in a broad spectrum of human and animal disease. Karyopharm will work with scientists lead by Dr. Dirk Daelemans of the Laboratory of Virology and Chemotherapy at the Rega Institute on the discovery and development of novel SINE CRM1 inhibitors. Together, the groups will expand the portfolio of Karyopharm's SINE CRM1 antagonists for the treatment of cancer, autoimmune diseases and viral disorders.

Dr. Dirk Daelemans and his colleagues at the Rega Institute have done pioneering work in the area of nuclear export modulation, particularly in their roles in viral replication. Dr. Daelemans said, "We are very pleased to be working with the team at Karyopharm, as they are in a leading position to move our combined portfolio of compounds into development for the treatment of human diseases."  Sharon Shacham, PhD, MBA, Karyopharm's CSO and Head of R&D, commented, "This collaboration with the Rega Institute, one of the world's leaders in elucidation of mechanism of action of biologically active compounds, further strengthens our research and development platform dedicated to bringing the first nuclear export inhibitors to the clinic for cancer and other disorders." It is anticipated that the collaboration will discover novel CRM1 inhibitors, beyond those already patented by Karyopharm.

About Karyopharm

Karyopharm is a preclinical-stage biopharmaceutical company leading the development of small molecule modulators of nuclear transport.  The Company was founded by Drs. Sharon Shacham, Michael Kauffman, Giulio Draetta and Ronald DePinho in 2008.  Karyopharm completed a $20M Series A financing in October, 2010, and has won several grants/awards including a Biotech Investment Award by the Multiple Myeloma Research Foundation in 2010. Karyopharm's first program is directed towards the Selective Inhibition of Nuclear Export – its SINE program – targeting CRM1, the major nuclear export protein. By inhibiting the nuclear export of tumor suppressor proteins, Karyopharm's drug candidates force the activation of the cell's key tumor suppressor and anti-inflammatory  pathways including p53, p21, pRB, FoxO, and the inhibitor of NF-kB (i.e., IkB).  Karyopharm anticipates entering the clinic in 2012 with its first SINE for the treatment of various cancers.  The Company is also evaluating the use of SINE in autoimmune, viral and dermatologic disorders.  Karyopharm Therapeutics is located in Natick, Massachusetts.

About K.U.Leuven and the Rega Institute for Medical Research

K.U.Leuven, founded in 1425, is the largest university in Belgium, located in Leuven (Flanders), with a wealth of excellent research and a strong reputation and track-record in technology transfer through K.U.Leuven Research & Development (LRD). More than 6,000 researchers from more than 120 countries concentrate on curiosity-driven and ground-breaking strategic research, as well as targeted and demand-driven research. The Rega Institute for Medical Research is a biomedical research institute of K.U.Leuven that comprises the Laboratory of Virology and Chemotherapy. Many patients have already been treated with drugs that were initially discovered at the Rega Institute.

CONTACT: Michael Kauffman, +1-617-803-0097, mkauffman@karyopharm.com


'/>"/>
SOURCE Karyopharm Therapeutics Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Karyopharm Therapeutics Inc. Appoints Michael Kauffman, MD, PhD, as Chief Executive Officer
2. Karyopharm Therapeutics Inc. Closes $20 Million Series A Financing to Advance Pipeline of Novel Nuclear Transport Modulators for Cancer, Inflammation and Other Disorders
3. Echo Therapeutics Hires Product Development Management Executive
4. Prime Therapeutics Demonstrates Willingness to Show Actual Pharmacy Costs
5. Echo Therapeutics Announces Positive Results of Clinical Trial of Its Symphony® Continuous Glucose Monitoring System
6. Womens Health Therapeutics, Analysis and Market Forecasts to 2016 - High Unmet Need will Drive the Uptake of Novel Drugs in the Menopause and Osteoporosis Markets
7. Metabolic Disorders Therapeutics Market to 2017 - Patent Expiry of Lipitor in 2011 will Negatively Impact Dyslipidemia Market Value
8. Argos Therapeutics Late Scientific Co-founder Ralph Steinman, M.D., Awarded Nobel Prize in Medicine for Discovery of Dendritic Cells as Critical Sentinels of Immune System
9. Orexigen® Therapeutics Presents Multiple Contrave® Data Presentations at the 29th Annual Scientific Meeting of The Obesity Society
10. Acute Ischemic Stroke (AIS) Therapeutics - Pipeline Assessment and Market Forecasts to 2018
11. Independent Radiology Assessment Panel Results Confirm Statistical Significance of Response and Progression Endpoints of Cell Therapeutics Pixantrone PIX301 Pivotal Trial
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/4/2016)...  AMRI (NASDAQ:  AMRI) today announced that Anthony J. ... of Pfizer Global Supply, has been elected to the AMRI ... addition, the Company announced that Mr. Gabe Leung , ... has retired from the AMRI Board of Directors in order ... ventures.  William S. Marth , President and ...
(Date:2/4/2016)... India , February 4, 2016 ... the new Market Research Report "North American Automated External ... Fully-Automated External Defibrillators), by End-User (Public Facilities, Hospitals, Homecare ... American automated external defibrillators (AED) report defines and segments ... the revenue. This market is estimated to grow to ...
(Date:2/4/2016)... India , February 4, 2016 ... market research report "Digital X-ray Market by Application (Mammography, Dental, ... Type of System, End User (Diagnostic Center, Hospitals), Price - ... is expected to reach USD 10.46 Billion by 2020 from ... from 2015 to 2020. Brow se 270 ...
Breaking Medicine Technology:
(Date:2/5/2016)... , ... February 05, 2016 , ... Stuart Bentkover, ... technology, the PicoSure. Designed to provide the most effective tattoo removal today, Dr. Bentkover ... unmatched results. , Developed by Cynosure, the PicoSure has been approved by the Food ...
(Date:2/5/2016)... ... February 05, 2016 , ... In sleep, when the defenses of ... A hallmark feature of patients with eating disorders is significant self-criticism, and consequently these ... and obsessions are regarded as maladaptive means for coping with this unease, but also ...
(Date:2/5/2016)... ... February 05, 2016 , ... On June ... Diseases, a continuing medical education (CME) event presented by the Association for Comprehensive ... a first for ACCORD, whose mission is to provide education, tools, and resources ...
(Date:2/5/2016)... Atascadero, CA (PRWEB) , ... February 05, 2016 , ... ... report on the benefits of having a tankless water heater. To view the report, ... of water heaters: tank and tankless. While each has their pros and cons, the ...
(Date:2/4/2016)... Verdes, CA (PRWEB) , ... February 04, 2016 ... ... at the "It's All About YOU Re-Treat" on February 19-21, 2016, in ... Re-Treat" is at Rancho Palos Verdes, California. These 30 professional speakers, including Clinical ...
Breaking Medicine News(10 mins):